Levothyroxine sodium and Pegintron drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Levothyroxine sodium (levothyroxine sodium) and Pegintron (peginterferon alfa-2b). Common drug interactions include transaminases increased among females and neutrophil count decreased among males.

The phase IV clinical study analyzes what interactions people have when they take Levothyroxine sodium and Pegintron. It is created by eHealthMe based on reports of 58 people who take the same drugs from the FDA, and is updated regularly.

What is Levothyroxine sodium?

Levothyroxine sodium has active ingredients of levothyroxine sodium. It is often used in hypothyroidism. eHealthMe is studying from 129,814 Levothyroxine sodium users. Check the latest studies of Levothyroxine sodium.

What is Pegintron?

Pegintron has active ingredients of peginterferon alfa-2b. It is often used in hepatitis c. eHealthMe is studying from 10,326 Pegintron users. Check the latest studies of Pegintron.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Sep, 03, 2026

58 people who take Levothyroxine sodium and Pegintron together, and have interactions are studied.

Levothyroxine sodium and Pegintron drug interactions.

What are the common drug interactions of Levothyroxine Sodium and Pegintron, by gender? *:

female:

  1. Transaminases increased
  2. Chills (felling of cold)
  3. Feeling hot
  4. Mood altered (changes in mood)
  5. White blood cell count decreased
  6. Abdominal pain
  7. Amenorrhoea (absence of a menstrual period in a woman of reproductive age)
  8. Anxiety
  9. Full blood count decreased
  10. Influenza like illness

male:

  1. Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
  2. Decreased appetite
  3. Hyperuricaemia (level of uric acid in the blood that is abnormally high)
  4. Vomiting
  5. Chills (felling of cold)
  6. Weight decreased
  7. White blood cell count decreased
  8. Anaemia (lack of blood)
  9. Depression
  10. Dizziness

What are the common drug interactions of Levothyroxine Sodium and Pegintron, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Haemoglobin decreased
  2. Leukopenia (less number of white blood cells in blood)
  3. Neutropenia (an abnormally low number of neutrophils)

30-39:

n/a

40-49:

  1. Cardiac death
  2. Abdominal pain
  3. Chest discomfort
  4. Cold sweat
  5. Cough
  6. Dysphonia (speech disorder attributable to a disorder of phonation)
  7. Face oedema (swelling of face)
  8. Fatigue (feeling of tiredness)
  9. Hyperhidrosis (abnormally increased sweating)
  10. Injection site pruritus (severe itching at injection site)

50-59:

  1. Malaise (a feeling of general discomfort or uneasiness)
  2. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  3. Platelet count decreased
  4. Psychomotor hyperactivity (feelings of extreme restlessness)
  5. Radical hysterectomy
  6. Weight increased
  7. Ankle fracture
  8. Balance disorder
  9. Fall
  10. Feeling hot

60+:

  1. Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
  2. Decreased appetite
  3. Pyrexia (fever)
  4. Vomiting
  5. Weight decreased
  6. Chills (felling of cold)
  7. Diarrhoea
  8. Platelet count decreased
  9. Asthenia (weakness)
  10. Fatigue (feeling of tiredness)

What are the existing conditions these people have? *

  1. High Blood Pressure: 4 people, 6.90%
  2. Diabetes: 4 people, 6.90%

* Approximation only. Some reports may have incomplete information.

Do you take Levothyroxine sodium and Pegintron?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Levothyroxine sodium and Pegintron:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Levothyroxine sodium:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Pegintron:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Levothyroxine sodium and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Pegintron and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on levothyroxine sodium and peginterferon alfa-2b (the active ingredients of Levothyroxine sodium and Pegintron, respectively), and Levothyroxine sodium and Pegintron (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: